[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30.
https://doi.org/10.3322/caac.21590
|
[3]
|
元玫雯, 王宏昊, 段如菲, 徐坤鹏, 胡尚英, 乔友林, 张勇, 赵方辉. 2016年中国归因于人乳头瘤病毒感染的肿瘤发病与死亡分析[J]. 中华流行病学杂志, 2022, 43(5): 702-708.
|
[4]
|
Ingrand, I., Defossez, G., Lafay-Chebassier, C., Chavant, F., Ferru, A., Ingrand, P. and Pérault-Pochat, M.C. (2020) Serious Adverse Effects Occurring after Chemotherapy: A General Cancer Registry-Based Incidence Sur-vey. British Journal of Clinical Pharmacology, 86, 711-722. https://doi.org/10.1111/bcp.14159
|
[5]
|
Planchard, D., Popat, S., Kerr, K., Van Schil, P.E., Hellmann, M.D., Peters, S., et al. (2019) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 30, 863-870. https://doi.org/10.1093/annonc/mdy474
|
[6]
|
Abdel, K.N. and Kelly, K. (2019) Role of Targeted Therapy and Im-mune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. The Oncologist, 24, 1270-1284.
https://doi.org/10.1634/theoncologist.2018-0112
|
[7]
|
Camidge, D.R., Pao, W. and Sequist, L.V. (2014) Acquired Resistance to TKIs in Solid Tumours: Learning from Lung Cancer. Nature Reviews Clinical Oncology, 11, 473-481. https://doi.org/10.1038/nrclinonc.2014.104
|
[8]
|
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[9]
|
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639.
https://doi.org/10.1056/NEJMoa1507643
|
[10]
|
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenk-iste, J., Mazieres, J., et al. (2016) Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846.
https://doi.org/10.1016/S0140-6736(16)00587-0
|
[11]
|
Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., et al. (2015) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomized Controlled Trial. The Lancet, 387, 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
|
[12]
|
Sundar, R., Cho, B.C., Brahmer, J.R. and Soo, R.A. (2015) Nivolumab in NSCLC: Latest Evidence and Clinical Potential. Therapeutic Advances in Medical Oncology, 7, 85-96. https://doi.org/10.1177/1758834014567470
|
[13]
|
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. and Honjo, T. (2001) PD-1 Immunoreceptor Inhibits B Cell Receptor-Mediated Signaling by Recruiting Src Homology 2-Domain-Containing Tyrosine Phosphatase 2 to Phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 98, 13866-13871.
https://doi.org/10.1073/pnas.231486598
|
[14]
|
Chauhan, D.S., Mudaliar, P., Basu, S., Aich, J. and Paul, M.K. (2022) Tumor-Derived Exosome and Immune Modulation. In: Paul, M.K., Eds., Extracellular Vesicles, IntechOpen. https://doi.org/10.5772/intechopen.103718
|
[15]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[16]
|
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., et al. (2022) Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 12, Article 799455. https://doi.org/10.3389/fimmu.2021.799455
|
[17]
|
Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
|
[18]
|
Lahiri, A., Maji, A., Potdar, P.D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A. and Paul, M.K. (2023) Lung Cancer Immunotherapy: Progress, Pitfalls, and Promises. Molecu-lar Cancer, 22, Article No. 40.
https://doi.org/10.1186/s12943-023-01740-y
|
[19]
|
高磊, 俞阳, 李晓梅, 刘乾, 尹振宇, 陈昊. 化疗与免疫检查点抑制剂联用对肿瘤治疗的作用[J/OL]. 解放军医学杂志: 1-11[2022-07-25].
https://kns.cnki.net/kcms2/article/abstract?v=KTWJcyGkBkCExXube66KZJbWU0ZvgXrwIMSz0aPwu94OKXxfieUWvVq1eInQpSk7uX2WXoDM7OLUBz2rTGplyA5seopv-fouuYvHD7gTa4JuXQVr6d4xfFDfUhF-cy8ScKryRlsHl60=&uniplatform=NZKPT&language=CHS
|
[20]
|
Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028.
https://doi.org/10.1056/NEJMoa1501824
|
[21]
|
Garon, E.B., Hellmann, M.D., Rizvi, N.A., Carcereny, E., Leighl, N.B., Ahn, M.J., Eder, J.P., Balmanoukian, A.S., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S.S., Felip, E., Goldman, J.W., Scalzo, C., Jensen, E., Kush, D.A. and Hui, R. (2019) Five-Year Overall Survival for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527.
https://doi.org/10.1200/JCO.19.00934
|
[22]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774
|
[23]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leal, T.A., Riess, J.W., Jensen, E., Zhao, B., Pietanza, M.C. and Brahmer, J.R. (2021) Five-Year Outcomes with Pembrolizumab versus Chem-otherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, 39, 2339-2349.
https://doi.org/10.1200/JCO.21.00174
|
[24]
|
Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., Castro Jr, G., Srimuninnimit, V., Laktionov, K.K., Bondarenko, I., Kubota, K., Lubiniecki, G.M., Zhang, J., Kush, D., Lopes, G. and KEYNOTE-042 Investigators. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830.
|
[25]
|
Gettinger, S., Rizvi, N.A., Chow, L.Q., Bor-ghaei, H., Brahmer, J., Ready, N., et al. (2016) Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 34, 2980-2987.
https://doi.org/10.1200/JCO.2016.66.9929
|
[26]
|
Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J.M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein Jr, G.R., Villaruz, L.C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W.J., Bhagavatheeswaran, P., Chen, A.C., Socinski, M.A. and CheckMate 026 Investigators (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2415-2426.
https://doi.org/10.1056/NEJMoa1613493
|
[27]
|
Peters, S., Gettinger, S., Johnson, M.L., Jänne, P.A., Garassino, M.C., Christoph, D., et al. (2017) Phase II Trial of Atezolizumab as First-Line Orsubsequent Therapy for Patients with Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 35, 2781-2789.
https://doi.org/10.1200/JCO.2016.71.9476
|
[28]
|
Herbst, R.S., Giaccone, G., de Marinis, F., et al. (2020) Atezoli-zumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England Journal of Medicine, 383, 1328-1339. https://doi.org/10.1056/NEJMoa1917346
|
[29]
|
Verschraegen, C.F., Jerusalem, G., McClay, E.F., Ian-notti, N., Redfern, C.H., Bennouna, J., Chen, F.L., Kelly, K., Mehnert, J., Morris, J.C., Taylor, M., Spigel, D., Wang, D., Grote, H.J., Zhou, D., Munshi, N., Bajars, M. and Gulley, J.L. (2020) Efficacy and Safety of First-Line Avelumab in Pa-tients with Advanced Non-Small Cell Lung Cancer: Results from a Phase Ib Cohort of the JAVELIN Solid Tumor Study. Journal for ImmunoTherapy of Cancer, 8, e001064.
https://doi.org/10.1136/jitc-2020-001064
|
[30]
|
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H.M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D.M., Yancopou-los, G.D., Gullo, G., Lowy, I. and Rietschel, P. (2021) Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial. The Lancet, 397, 592-604.
https://doi.org/10.1016/S0140-6736(21)00228-2
|
[31]
|
Rapoport, B.L. and Anderson, R. (2019) Realizing the Clini-cal Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. International Journal of Molecular Sciences, 20, Article 959.
https://doi.org/10.3390/ijms20040959
|
[32]
|
于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(1): 48-52.
https://doi.org/10.16138/j.1673-6087.2022.01.009
|
[33]
|
Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimi-trakopoulou, V.A., Patnaik, A., Powell, S.F., et al. (2016) Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. The Lancet Oncology, 17, 1497-1508.
https://doi.org/10.1016/S1470-2045(16)30498-3
|
[34]
|
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E. and Felip, E. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[35]
|
Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., Noguchi, K., Souza, F. and Kurata, T. (2021) Pem-brolizumab plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Ja-pan Study. Cancer Science, 112, 3255-3265.
https://doi.org/10.1111/cas.14980
|
[36]
|
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y., Bas, T., Piperdi, B. and Halmos, B. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15, 1657-1669. https://doi.org/10.1016/j.jtho.2020.06.015
|
[37]
|
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H.J., Kozuki, T., Huang, K.C., Graupner, V., Sun, S.W., Hoang, T., Jes-sop, H., McCleland, M., Ballinger, M., Sandler, A. and Socinski, M.A. (2020) Atezolizumab in Combination with Car-boplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results from a Randomized Phase III Trial. Journal of Thoracic Oncology, 15, 1351-1360.
https://doi.org/10.1016/j.jtho.2020.03.028
|
[38]
|
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H.J.., Kopp, H.G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Sandler, A., Lin, W., Ochi Lohmann, T., Archer, V., Wang, L., Kowanetz, M. and Cappuzzo, F. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Meta-static Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937.
https://doi.org/10.1016/S1470-2045(19)30167-6
|
[39]
|
Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Co-bo, M., Longeras, P.D., Goldschmidt Jr, J., Novello, S., Orlandi, F., Sanborn, R.E., Szalai, Z., Ursol, G., Mendus, D., Wang, L., Wen, X., McCleland, M., Hoang, T., Phan, S. and Socinski, M.A. (2021) Atezolizumab plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 16, 653-664.
https://doi.org/10.1016/j.jtho.2020.11.025
|
[40]
|
Zhang, L., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Stefaniak, V., Lin, Y., Wang, S., Zhang, W., Sun, L. and Yang, Y. (2022) Final Overall Survival Data of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Lung Cancer, 171, 56-60. https://doi.org/10.1016/j.lungcan.2022.07.013
|
[41]
|
Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., Zhou, J., Zhou, C., Li, B., Li, J., Fan, M., Cui, J., Li, Y., Zhao, H., Fang, J., Xue, J., Hu, C., Sun, P., Du, Y., Zhou, H., Wang, S. and Zhang, W. (2021) Sintilimab plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results from a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 16, 1501-1511. https://doi.org/10.1016/j.jtho.2021.04.011
|
[42]
|
Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., Wang, Q., Cheng, Y., Wu, F., Chen, J., Lin, X., Wang, Y., Huang, J., Cui, J., Cao, L., Liu, Y., Zhang, Y., Pan, Y., Zhao, J., Wang, L., Chang, J., Chen, Q., Ren, X., Zhang, W., Fan, Y., He, Z., Fang, J., Gu, K., Dong, X., Jin, F., Gao, H., An, G., Ding, C., Jiang, X., Xiong, J., Zhou, X., Hu, S., Lu, P., Liu, A., Guo, S., Huang, J., Zhu, C., Zhao, J., Gao, B., Chen, Y., Hu, C., Zhang, J., Zhang, H., Zhao, H., Tai, Y., Ma, X., Shi, W. and CameL Study Group (2023) Camrelizumab plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. Journal of Thoracic Oncology, 18, 628-639. https://doi.org/10.1016/j.jtho.2022.12.017
|
[43]
|
Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., Wang, R., Li, X., Zhang, W., Zhang, Y., Hu, S., Guo, R., Shi, J., Wang, Z., Cao, P., Wang, D., Fang, J., Luo, H., Geng, Y., Xing, C., Lv, D., Zhang, Y., Yu, J., Cang, S., Yang, Z., Shi, W., Zou, J., Zhou, C. and CameL-sq Study Group (2022) Camrelizumab plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557. https://doi.org/10.1016/j.jtho.2021.11.018
|
[44]
|
Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., Li, W., Cui, J., Wang, D., Liao, W., Zhou, J., Wang, Z., Sun, Y., Qiu, X., Gao, J., Bao, Y., Liang, L. and Wang, M. (2021) Tislelizumab plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 16, 1512-1522. https://doi.org/10.1016/j.jtho.2021.05.005
|
[45]
|
Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., Feng, G., Ying, K., Zhuang, W., Zhou, J., Wu, J., Leaw, S.J., Zhang, J., Lin, X., Liang, L. and Yang, N. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Ad-vanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 709-717. https://doi.org/10.1001/jamaoncol.2021.0366
|
[46]
|
Paz-Ares, L.G., Ramalingam, S.S., Ciuleanu, T.E., Lee, J.S., Urban, L., Caro, R.B., Park, K., Sakai, H., Ohe, Y., Nishio, M., Audigier-Valette, C., Burgers, J.A., Pluzanski, A., Sangha, R., Gallardo, C., Takeda, M., Linardou, H., Lupinacci, L., Lee, K.H., Caserta, C., Provencio, M., Carcereny, E., Otterson, G.A., Schenker, M., Zurawski, B., Alexandru, A., Vergnenegre, A., Raimbourg, J., Feeney, K., Kim, S.W., Borghaei, H., O’Byrne, K.J., Hellmann, M.D., Memaj, A., Nathan, F.E., Bushong, J., Tran, P., Brahmer, J.R. and Reck, M. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308. https://doi.org/10.1016/j.jtho.2021.09.010
|
[47]
|
Paz-Ares, L., Ciuleanu, T.E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P.J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., John, T., Carbone, D.P., Mead-ows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J. and Reck, M. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An In-ternational, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0
|
[48]
|
Huang, Q., Kemnade, J., Cornwell, L., et al. (2022) Non-Small Cell Lung Cancer in the Era of Immunotherapy. Seminars in Oncology, 49, 337-343. https://doi.org/10.1053/j.seminoncol.2022.06.009
|
[49]
|
李光韬, 张卓莉. 自身免疫性疾病与发热[J]. 中国实用内科杂志, 2016, 36(12): 1032-1035.
|
[50]
|
Doroshow, D.B., Bhalla, S., Beasley, M.B., Sholl, L.M., Kerr, K.M., Gnjatic, S., Wistuba, I.I., Rimm, D.L., Tsao, M.S. and Hirsch, F.R. (2021) PD-L1 as a Biomarker of Response to Im-mune-Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 18, 345-362. https://doi.org/10.1038/s41571-021-00473-5
|
[51]
|
Shen, X. and Zhao, B. (2018) Efficacy of PD-1 or PD-L1 Inhib-itors and PD-L1 Expression Status in Cancer: Meta-Analysis. The BMJ, 362, k3529. https://doi.org/10.1136/bmj.k3529
|
[52]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint In-hibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249.
https://doi.org/10.1146/annurev-pathol-042020-042741
|